Get the Stockscreener App
1.39
0.72%
0.01
After Hours:
1.42
0.03
+2.16%
Vor Biopharma Inc stock is traded at $1.39, with a volume of 290.84K.
It is up +0.72% in the last 24 hours and up +16.81% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
See More
Previous Close:
$1.38
Open:
$1.38
24h Volume:
290.84K
Relative Volume:
0.38
Market Cap:
$170.80M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-0.8476
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
-9.15%
1M Performance:
+16.81%
6M Performance:
+50.43%
1Y Performance:
-42.80%
1-Day Range:
$1.34
$1.449
1-Week Range:
$1.3225
$1.59
52-Week Range:
$0.63
$2.50
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
1.39 | 170.80M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
SEC Form 424B3 filed by Vor Biopharma Inc. - Quantisnow
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $11.36 - MarketBeat
FOXO Technologies Announces Special Shareholders Meeting - Defense World
Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by StockNews.com - Defense World
Arcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.com - Defense World
AngioDynamics (ANGO) to Host NanoKnife Investor Event - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Allurion Technologies (NYSE: ALUR) Enters into Omnibus Amendment to Amend Note Purchase Agreement and RIFAsOn January 7, 2025, Allurion Technologies, Inc. (NYSE: ALUR) and Allurion OpCo entered into an Omnibus Amendment with various entitie - Defense World
Vor Biopharma Strengthens Board with New Appointment - TipRanks
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors - GlobeNewswire Inc.
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors - Yahoo Finance
Vor biopharma sees significant stock acquisition by Reid Hoffman - Investing.com South Africa
Vor Biopharma's chief medical officer sells shares worth $12,917 By Investing.com - Investing.com Australia
Vor Biopharma's chief medical officer sells shares worth $12,917 - Investing.com India
Vor Biopharma’s chief medical officer sells shares worth $12,917 By Investing.com - Investing.com Nigeria
Vor Biopharma Inc. (NYSE:VOR) Insider Sells $12,917.50 in Stock - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc - GuruFocus.com
Vor Biopharma's SWOT analysis: promising AML therapy stock faces pivotal year - Investing.com India
Vor Biopharma’s SWOT analysis: promising AML therapy stock faces pivotal year - Investing.com Nigeria
Vor Biopharma's SWOT analysis: promising AML therapy stock faces pivotal year By Investing.com - Investing.com South Africa
Vor Biopharma Inc. announced that it has received $55.55 million in funding from RA Capital Management, L.P. - Marketscreener.com
Vor Bio Announces $55.6 Million Private Placement - Marketscreener.com
Vor Biopharma Inc. Announces $55.6 Million Private Placement - Defense World
Vor Biopharma Secures $55.6M for Cancer Therapy Trials - Yahoo Finance
Vor Biopharma Inc. announced that it expects to receive $55.55 million in funding - Marketscreener.com
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Ne - GuruFocus.com
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47% - Yahoo Finance UK
What's Going On With Vor Biopharma Shares Friday? - Benzinga
Vor BioPharma stocks surge 33% after private placement By Investing.com - Investing.com Canada
Vor Bio announces $55.6M private placement, shares soar - Seeking Alpha
Vor Biopharma : Bio Announces $55.6 Million Private Placement Form 8 K - Marketscreener.com
Vor Bio Secures $55.6M Investment Led by Reid Hoffman, Extends Runway for Key 2025 Trial Results - StockTitan
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate - Simply Wall St
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Vor Biopharma's SWOT analysis: stock shows promise amid AML treatment advances - Investing.com Canada
Vor Biopharma’s (VOR) Buy Rating Reiterated at HC Wainwright - Defense World
Vor Biopharma’s (VOR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
Vor Biopharma’s (VOR) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Vor Biopharma Announces Updated Clinical Data and FDA Feedback – - Defense World
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from Fda Regarding Registrational Trial Design - Marketscreener.com
Vor Biopharma : Bio Corporate Presentation December 2024 - Marketscreener.com
Vor Biopharma Reports Promising Phase 1/2 Study Results - TipRanks
Vor Bio Provides Clinical Update Further Validating - GlobeNewswire
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design - Marketscreener.com
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):